Critical Decisions Driving Next-Generation Cell Line Development

October 13, 2026 11 AM ET

The choices made during cell line development can have a lasting impact on productivity, scalability, regulatory success, and ultimately, time to market. As technologies such as precision genome engineering and next-generation sequencing continue to advance, biopharma teams have new opportunities to build stronger, more reliable cell line development strategies.

Join Bioprocess Online’s Tyler Menichiello and industry experts Ted Peters, Ph.D. (Immunome) and Ronan O’Kennedy, Ph.D. (ROK Bioconsulting) for an interactive discussion on the critical decisions that shape successful cell line development programs.

During this event, you’ll learn how to:

~ Make informed platform selection and cell engineering decisions

~ Strengthen clonality and characterization strategies

~ Improve downstream process performance and manufacturing outcomes

~ Avoid common development pitfalls that can create delays later

~ Prepare the CMC documentation needed to support FDA and EMA submissions

Whether you work with mammalian or microbial expression systems, you’ll walk away with practical insights for building a more efficient, scalable, and regulatory-ready cell line development strategy.

Reserve your spot and gain expert guidance on the decisions that matter most early in development.

FILL THE FORM BELOW

First Name *

Last Name *

Company Street Address *

Company Suite/Office *

Company Postal/Zip Code *

Company City *

Company State *

Company Country *

By submitting this content request, I have legitimate interest in the content and agree that Bioprocess Online, their partners, and the creators of any other content I have selected may contact me regarding news, products, and services that may be of interest to me.

YesNo

Which Cell Line Development priority is most critical for your current programs?

How soon is Cell Line Development or optimization needed for your program?

How is your organization currently approaching Cell Line Development? (select all that apply)
Fully outsourced to a CDMO/service providerHybrid model-internal dvpmt. & external partnersPrimarily in-house with selective outsourcingFully in-houseNot currently engaged in cell line development

Tell us about your current Cell Line Development program, including any priorities, challenges, or upcoming development needs.